15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $45.4B | $472M | 13.1% | 1.7% | -$636M | $3.8B | $4.2B |
| 2024 | $40.6B | $1.2B | 15.3% | 4.2% | $544M | $2.9B | $4.7B |
| 2023 | $34.1B | $1.1B | 15.9% | 4.6% | $1.6B | $2.2B | $4.8B |
| 2022 | $32.0B | $792M | 15.0% | 3.7% | $682M | $2.2B | $4.0B |
| 2021 | $27.8B | $659M | 14.6% | 3.7% | $2.0B | $2.2B | $4.4B |
| 2020 | $19.4B | $673M | 12.8% | 5.6% | $1.8B | $2.1B | $4.2B |
| 2019 | $16.8B | $737M | 13.7% | 6.2% | $377M | $1.3B | $2.5B |
| 2018 | $18.9B | $707M | 13.3% | 6.0% | -$344M | $1.0B | $2.8B |
| 2017 | $19.9B | -$512M | 9.1% | -2.8% | $718M | $1.3B | $3.2B |
| 2016 | $17.8B | $52M | 9.7% | 1.7% | $497M | $1.6B | $2.8B |
| 2015 | $14.2B | $143M | 10.8% | 2.7% | $993M | $1.4B | $2.3B |
| 2014 | $9.7B | $62M | 10.3% | 2.0% | $945M | $690M | $1.5B |
| 2013 | $6.6B | $53M | 12.8% | 2.1% | — | $737M | $936M |
| 2012 | $5.9B | $10M | 0.0% | 0.7% | — | $274M | $796M |
| 2011 | $4.5B | $21M | 0.0% | 3.0% | — | $218M | $494M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $10.8B | $14M | 14.1% | 0.8% | $1.1B | $3.8B | $5.3B |
| Dec '25 | $11.4B | -$160M | 10.9% | -1.4% | -$297M | $3.8B | $4.2B |
| Sep '25 | $11.5B | $79M | 12.5% | 1.2% | -$163M | $3.7B | $4.2B |
| Jun '25 | $11.4B | $255M | 14.0% | 3.3% | -$344M | $3.4B | $4.5B |
| Mar '25 | $11.1B | $298M | 15.0% | 3.9% | $168M | $3.6B | $4.9B |
| Dec '24 | $10.5B | $251M | 14.2% | 3.6% | -$235M | $2.9B | $4.7B |
| Sep '24 | $10.3B | $326M | 16.4% | 4.5% | $838M | $2.3B | $4.7B |
| Jun '24 | $9.9B | $301M | 15.3% | 4.4% | -$246M | $2.2B | $4.4B |
| Mar '24 | $9.9B | $301M | 15.3% | 4.3% | $187M | $2.2B | $4.5B |
| Dec '23 | $9.0B | $216M | 17.6% | 3.5% | -$685M | $2.2B | $4.8B |
| Sep '23 | $8.5B | $245M | 14.5% | 4.2% | $923M | $2.2B | $5.6B |
| Jun '23 | $8.3B | $309M | 15.5% | 5.3% | $456M | $2.2B | $4.9B |
| Mar '23 | $8.1B | $321M | 15.7% | 5.6% | $884M | $2.2B | $4.6B |
| Dec '22 | $8.2B | $56M | 15.0% | 1.3% | -$222M | $2.2B | $4.0B |
| Sep '22 | $7.9B | $230M | 14.9% | 4.2% | $223M | $2.2B | $4.2B |
| Jun '22 | $8.1B | $248M | 14.7% | 4.5% | $341M | $2.2B | $4.3B |
| Mar '22 | $7.8B | $258M | 15.5% | 4.8% | $340M | $2.2B | $4.8B |
| Dec '21 | $7.4B | $103M | 14.1% | 2.6% | $576M | $2.2B | $4.4B |
| Sep '21 | $7.0B | $143M | 14.1% | 3.1% | $434M | $2.1B | $4.4B |
| Jun '21 | $6.8B | $185M | 14.4% | 4.0% | $480M | $2.1B | $4.6B |
How the market has priced MOH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Molina Healthcare, Inc.'s revenue has grown 18.5% per year, and net income declined 6.8% per year. These are computed facts, not advice.
As of FY2025, Molina Healthcare, Inc. reported $3.8B of total debt against $4.2B of cash; operating income covered interest expense 4.1×.
In FY2025, gross margin was 13.1%, operating margin 1.7%, and net margin 1.0%.
As of Jun '26, Molina Healthcare, Inc. traded at a price-to-earnings ratio of about 23.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.